ADMA Biologics Files 8-K with Exhibits
Ticker: ADMA · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, exhibits, regulation-fd
TL;DR
ADMA Biologics filed an 8-K on 3/27/26 with exhibits, no major news yet.
AI Summary
ADMA Biologics, Inc. filed an 8-K on March 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes various exhibits, such as an iXBRL 8-K document, graphic images, and XBRL data files, but does not contain specific financial figures or operational updates in the provided text.
Why It Matters
This filing indicates ADMA Biologics is providing updated information or exhibits to the SEC, which could contain details relevant to investors, though the specific content is not detailed here.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with exhibits and does not appear to contain material adverse information.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Filer
- 0001368514 (company) — CIK Number
- 2026-03-27 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is primarily for Regulation FD Disclosure (Item 7.01) and to report Financial Statements and Exhibits (Item 9.01).
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 27, 2026.
What types of documents are included as exhibits in this filing?
The exhibits include an iXBRL 8-K document, graphic images, and XBRL data files (schema, label, and presentation linkbases).
What is ADMA Biologics' mailing address as listed in the filing?
ADMA Biologics' mailing address is C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY NJ 07446.
What SIC code is associated with ADMA Biologics?
The SIC code associated with ADMA Biologics is 2836, which pertains to Biological Products (No Diagnostic Substances).
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2026-03-27 07:05:42
Filing Documents
- ef20069109_8k.htm (8-K) — 29KB
- ef20069109_ex99-1.htm (EX-99.1) — 50KB
- image1.jpg (GRAPHIC) — 159KB
- image2.jpg (GRAPHIC) — 74KB
- image3.jpg (GRAPHIC) — 80KB
- image4.jpg (GRAPHIC) — 58KB
- image5.jpg (GRAPHIC) — 54KB
- image6.jpg (GRAPHIC) — 4KB
- 0001140361-26-011569.txt ( ) — 806KB
- adma-20260327.xsd (EX-101.SCH) — 4KB
- adma-20260327_lab.xml (EX-101.LAB) — 21KB
- adma-20260327_pre.xml (EX-101.PRE) — 16KB
- ef20069109_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On March 27, 2026, ADMA Biologics, Inc. issued a press release, which is furnished hereto as Exhibit 99.1 and is incorporated by reference herein.*
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. Press Release, dated as of March 27, 2026 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) *The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. March 27, 2026 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer